Ono Teams Separately With Onyx And Concordia To Continue Its In-Licensing Oncology Expansion
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Ono Pharmaceutical has signed separate licensing agreements with Onyx and Concordia for oncology products, deals which the company said has caused it to lower its yearly forecast due to higher than expected in-licensing payments
You may also be interested in...
Merck Products Give Ono Pharma Renewed Life In Japan
TOKYO - Ono Pharma's drug portfolio is "going from maturity to decline," according to a Bank America Merrill Lynch analyst, but there are signs that in-licensed products from Merck, particularly antiemetic Emend (aprepitant), could bring new life to the company
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).